TY - JOUR
T1 - The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes
AU - Thomas, M. C.
N1 - Funding Information:
MCT has received research support from Boehringer Ingelheim. MCT has received honoraria for educational meetings performed in Australia and Internationally on behalf of Boehringer Ingelheim, Lilly, MSD, Novartis, AstraZeneca, Mylan, Sanofi, & Servier. MCT has been an advisory board member for MundiPharma, AstraZeneca, Lilly & MSD and a steering Committee member for ?Across Type 2 Diabetes?, and E3 sponsored by Boehringer Ingelheim & Eli Lilly and Company Alliance.
Publisher Copyright:
© 2021
PY - 2022/3
Y1 - 2022/3
N2 - Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a ‘pure’ type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to efficiently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it.
AB - Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a ‘pure’ type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to efficiently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it.
KW - Cardiovascular disease
KW - Diabetic complications
KW - Diabetic eye disease
KW - Diabetic foot disease
KW - Diabetic kidney disease
KW - Metabolic-associated fatty liver disease
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85121986263&partnerID=8YFLogxK
U2 - 10.1016/j.metabol.2021.154961
DO - 10.1016/j.metabol.2021.154961
M3 - Review Article
C2 - 34958818
AN - SCOPUS:85121986263
SN - 0026-0495
VL - 128
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
M1 - 154961
ER -